AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

MESOBLAST LTD

1.935

-0.060-3.01%

Volume:3.23M

Turnover:6.31M

Market Cap:2.51B

PE:-30.29

High:2.040

Open:1.990

Low:1.925

Close:1.995

52wk High:3.310

52wk Low:1.880

Shares:1.30B

Float Shares:786.49M

Volume Ratio:1.20

T/O Rate:0.41%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.064

EPS(LYR):-0.064

ROE:-9.86%

ROA:-4.11%

PB:3.07

PE(LYR):-30.29

Loading ...

Overview Company News Filings

Stock Track | Mesoblast Soars 8.93% Intraday on Upbeat Ryoncil Cell Therapy Earnings

Australia's Mesoblast Extends Gains on Upbeat Ryoncil Cell Therapy Earnings

Founder Led Stocks With Real Skin In The Game

Simply Wall St.

Mesoblast (ASX:MSB) Is Up 8.7% After Strong Ryoncil Debut And FDA BLA Milestone - Has The Bull Case Changed?

Simply Wall St.

Why Retail Investors Are Tracking These 3 Australian Founder Led Stocks

Simply Wall St.

Australia's Mesoblast Hits over Two Week High on Upbeat Ryoncil Revenue

Stock Track | Mesoblast Soars 5% Intraday on Strong Ryoncil Revenue Results

Mesoblast Posts Ryoncil Q4 Net Revenue of $36M

Ryoncil® Delivers Net Revenue of Us$36m for the Fourth Quarter Ended 30 June 2026

THOMSON REUTERS

Press Release: Ryoncil(r) Delivers Net Revenue of Us$36m for the Fourth Quarter Ended 30 June 2026

Mesoblast Ltd - Ryoncil Q4 Net Revenue of Us$36m and Us$115m for Full Year

THOMSON REUTERS

3 Founder Led Australian Stocks Retail Investors Are Tracking Right Now

Simply Wall St.

3 Australian Founder Led Stocks With Long Term Skin In The Game

Simply Wall St.

Mesoblast Requests Modular Review of BLA for Rexlemestrocel-l in End-stage Heart Failure with LVAD

3 Founder Led ASX Stocks Retail Investors Are Watching For Management Alignment

Simply Wall St.

Why Mesoblast (ASX:MSB) Is Up 9.3% After FDA Accepts Modular BLA Review For Rexlemestrocel-L

Simply Wall St.

Founder Led Stocks Retail Investors Are Watching In Australia Right Now

Simply Wall St.

Is Mesoblast (ASX:MSB) Undervalued Following FDA Progress For Rexlemestrocel L?

Simply Wall St.

Stock Track | Mesoblast Soars 5.12% Intraday on FDA BLA Filing Number for Rexlemestrocel-L Heart Failure Therapy

Mesoblast Receives Biologics License Application Filing Number From US FDA; Shares Up 3%

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/stock/MSB.AU/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"MSB.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","market":"AU","secType":"STK","nameCN":"MESOBLAST LTD","latestPrice":1.935,"timestamp":1791436320000,"preClose":1.995,"halted":0,"volume":3232575,"delay":0,"changeRate":-0.030075187969924838,"nameEN":"MESOBLAST LTD","floatShares":786490638,"shares":1296862776,"eps":-0.06387478240853967,"marketStatus":"Closed","change":-0.06,"latestTime":"10-08 16:12:00 AEDT","open":1.99,"high":2.04,"low":1.925,"amount":6312384,"amplitude":0.057644,"askPrice":1.945,"askSize":530,"bidPrice":1.93,"bidSize":166909,"shortable":3,"etf":0,"ttmEps":-0.06387478240853967,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1791500400000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":1.995,"openAndCloseTimeList":[[1791414000000,1791435600000]],"volumeRatio":1.199848,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"MSB.AU","preClose":1.995,"auctionPrice":1.935,"auctionVolume":403083,"auctionTime":1791436203501,"referencePrice":1.935,"referenceTime":1791438120458,"auction":3,"marketStatus":"盘后竞价","timestamp":1791436203501}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","floatShares":786490638,"roa":"-4.11%","roe":"-9.86%","lyrEps":-0.063875,"volumeRatio":1.199848,"shares":1296862776,"dividePrice":0,"high":2.04,"amplitude":0.057644,"preClose":1.995,"low":1.925,"week52Low":1.88,"pbRate":"3.07","psRate":"14.51","week52High":3.31,"institutionHeld":0,"latestPrice":1.935,"committee":0.993669,"eps":-0.06387478240853967,"divideRate":0,"volume":3232575,"delay":0,"ttmEps":-0.06387478240853967,"open":1.99,"prevYearClose":2.72,"prevWeekClose":2.04,"prevMonthClose":2.11,"prevQuarterClose":2.11,"fiveDayClose":2.07,"twentyDayClose":2.17,"sixtyDayClose":2.77,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MSB.AU\",params:#limit:5,,,undefined,":[{"date":"2026-08-26","symbol":"MSB.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787702400000,"name":null,"time":"","dateTimestamp":1787666400000,"actualEps":null},{"date":"2025-02-26","symbol":"MSB.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MSB.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MSB.AU\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1122101526","title":"Stock Track | Mesoblast Soars 8.93% Intraday on Upbeat Ryoncil Cell Therapy Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=1122101526","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122101526?lang=en_us&edition=fundamental","pubTime":"2026-07-13 08:50","pubTimestamp":1783903829,"startTime":"0","endTime":"0","summary":"Shares of Mesoblast Ltd (MSB.AU) are soaring, with the stock rising 8.93% during the intraday trading session.The significant price jump follows the company's announcement on Friday that its cell...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651643611","title":"Australia's Mesoblast Extends Gains on Upbeat Ryoncil Cell Therapy Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2651643611","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651643611?lang=en_us&edition=fundamental","pubTime":"2026-07-13 08:47","pubTimestamp":1783903622,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Mesoblast extends gains on upbeat Ryoncil cell therapy earnings** Shares of MesoblastMSB.AXextend gains, rising as much as 9.4% to A$2.45, their highest level since February 27** Stoc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nL4N43F00V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSB.AU","BK7067","BK7501","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650415750","title":"Founder Led Stocks With Real Skin In The Game","url":"https://stock-news.laohu8.com/highlight/detail?id=2650415750","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650415750?lang=en_us&edition=fundamental","pubTime":"2026-07-12 08:32","pubTimestamp":1783816325,"startTime":"0","endTime":"0","summary":"Founder led companies can offer something many investors value: clear alignment between leadership decisions and long term shareholder interests. With bond yields, inflation readings and energy prices all pulling markets in different directions, some investors are looking for leaders who are deeply tied to the long term outcome of their business, not just the next quarter. This Founder Led Companies screener focuses on stocks where decision makers have a personal legacy on the line. In this...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/4484222-main-header/1585186590706","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/4484222-main-header/1585186590706"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/consumer-services/asx-flt/flight-centre-travel-group-shares/news/founder-led-stocks-with-real-skin-in-the-game","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/consumer-services/asx-flt/flight-centre-travel-group-shares/news/founder-led-stocks-with-real-skin-in-the-game","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7070","BK7043","MAQ.AU","BK7046","BK7501","MQG.AU","MSB.AU","BK7067","BK7511","FLT.AU","BK7508","BK7042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650157507","title":"Mesoblast (ASX:MSB) Is Up 8.7% After Strong Ryoncil Debut And FDA BLA Milestone - Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2650157507","media":"Simply Wall St.","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650157507?lang=en_us&edition=fundamental","pubTime":"2026-07-12 08:28","pubTimestamp":1783816116,"startTime":"0","endTime":"0","summary":"In July 2026, Mesoblast reported that the FDA had accepted its Biologics License Application for rexlemestrocel‑L in preventing life‑threatening gastrointestinal bleeding in end‑stage heart failure patients with LVADs, while the therapy continued to benefit from Orphan Drug and RMAT designations under newly clarified, more flexible FDA guidance for rare diseases.\nSeparately, Mesoblast disclosed record Ryoncil net revenue of US$36,000,000 for the quarter and US$115,000,000 for its first full...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-is-up-87-after-strong-ryoncil-debut-and-fda","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-is-up-87-after-strong-ryoncil-debut-and-fda","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LABU","MSB","BK4585","BK4588","BK7508","BK4006","BK7501","BK7067","MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650131698","title":"Why Retail Investors Are Tracking These 3 Australian Founder Led Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2650131698","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650131698?lang=en_us&edition=fundamental","pubTime":"2026-07-10 23:45","pubTimestamp":1783698305,"startTime":"0","endTime":"0","summary":"With inflation, energy prices and central bank moves all pulling markets in different directions, many investors are looking for leaders whose interests are closely aligned with their own. Founder led companies often fit that profile, with executives who have personal capital, reputation and long term legacy tied to each decision. Our Founder Led Companies screener is designed to spotlight these businesses so you can focus on leadership quality while the macro data shifts around rates, trade...","market":"sg","thumbnail":"https://images.simplywall.st/asset/company-cover/4484222-main-header/1585186590706","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/4484222-main-header/1585186590706"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/consumer-services/asx-flt/flight-centre-travel-group-shares/news/why-retail-investors-are-tracking-these-3-australian-founder","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/consumer-services/asx-flt/flight-centre-travel-group-shares/news/why-retail-investors-are-tracking-these-3-australian-founder","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ISBC","IISV.AU","EIGA.AU","MAQ.AU","STW.AU","OZF.AU","QFN.AU","BBOZ.AU","BK7046","VAP.AU","XKO.AU","BK7508","XAO.AU","FLT.AU","IIGF.AU","BK7511","ZYAU.AU","BK7501","BK7070","BK7042","IOZ.AU","BK4211","E200.AU","QRE.AU","MQG.AU","SLF.AU","BK7043","MSB.AU","BEAR.AU","IMLC.AU","BK7067","GEAR.AU","VAS.AU","GIVE.AU","OZR.AU","DACE.AU","XJO.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650390190","title":"Australia's Mesoblast Hits over Two Week High on Upbeat Ryoncil Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2650390190","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650390190?lang=en_us&edition=fundamental","pubTime":"2026-07-10 12:50","pubTimestamp":1783659050,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Mesoblast hits over two week high on upbeat Ryoncil revenue** Shares of MesoblastMSB.AXrise 7.9% to A$2.265, their highest level since June 24** On track for best day since April 15 i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260710:nL4N43C0A9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7067","MSB.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128639414","title":"Stock Track | Mesoblast Soars 5% Intraday on Strong Ryoncil Revenue Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1128639414","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128639414?lang=en_us&edition=fundamental","pubTime":"2026-07-10 11:14","pubTimestamp":1783653296,"startTime":"0","endTime":"0","summary":"Mesoblast Ltd's stock soared 5.00% during intraday trading on FRIDAY, following the release of its quarterly financial results.The biotech company announced that its Ryoncil product delivered net...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650903463","title":"Mesoblast Posts Ryoncil Q4 Net Revenue of $36M","url":"https://stock-news.laohu8.com/highlight/detail?id=2650903463","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650903463?lang=en_us&edition=fundamental","pubTime":"2026-07-10 09:27","pubTimestamp":1783646852,"startTime":"0","endTime":"0","summary":"July 10 (Reuters) - Mesoblast Ltd::*RYONCIL Q4 NET REVENUE OF US$36M AND US$115M FOR FULL YEAR*Further company coverage: MSB.AX* ((Reuters.Briefs@thomsonreuters.com;))((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))Source Date/Time = 09-JUL-202622:45:23.123 GMT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260710:nRSD2z4bWQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7067","BK7508","MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650138908","title":"Ryoncil® Delivers Net Revenue of Us$36m for the Fourth Quarter Ended 30 June 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2650138908","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650138908?lang=en_us&edition=fundamental","pubTime":"2026-07-10 08:30","pubTimestamp":1783643405,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260710:nTUA369W1M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7501","BK7508","MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650390813","title":"Press Release: Ryoncil(r) Delivers Net Revenue of Us$36m for the Fourth Quarter Ended 30 June 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2650390813","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650390813?lang=en_us&edition=fundamental","pubTime":"2026-07-10 08:30","pubTimestamp":1783643400,"startTime":"0","endTime":"0","summary":"NEW YORK, July 09, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced Ryoncil(R) (remestemcel-","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BK7501","BK4575","MSB.AU","R","BK4150","MSB","BK7508","MESO","BK4022","BK4139","BK7067","MSC","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650970174","title":"Mesoblast Ltd - Ryoncil Q4 Net Revenue of Us$36m and Us$115m for Full Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2650970174","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650970174?lang=en_us&edition=fundamental","pubTime":"2026-07-10 07:58","pubTimestamp":1783641511,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260709:nFWN43B17F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK7067","MSB.AU","MESO","BK7501","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650945914","title":"3 Founder Led Australian Stocks Retail Investors Are Tracking Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2650945914","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650945914?lang=en_us&edition=fundamental","pubTime":"2026-07-09 10:33","pubTimestamp":1783564382,"startTime":"0","endTime":"0","summary":"With inflation worries, oil shocks and shifting interest rate expectations back in focus, many investors are looking for leaders who are personally invested in how their companies perform. Founder led stocks can offer exactly that, with management teams whose own legacies and wealth are closely tied to long term results. The Founder-Led Companies screener is designed to surface these businesses so you are not just backing an idea; you are backing the people behind it. Below, the article will...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/4484222-main-header/1585186590706","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/4484222-main-header/1585186590706"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/consumer-services/asx-flt/flight-centre-travel-group-shares/news/3-founder-led-australian-stocks-retail-investors-are-trackin-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/consumer-services/asx-flt/flight-centre-travel-group-shares/news/3-founder-led-australian-stocks-retail-investors-are-trackin-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["QRE.AU","BBOZ.AU","EIGA.AU","BK7042","BK7501","BK7070","IIGF.AU","IOZ.AU","BEAR.AU","ZYAU.AU","IMLC.AU","MAQ.AU","BK4211","BK7067","MSB.AU","OZR.AU","SLF.AU","XJO.AU","XKO.AU","DACE.AU","BK7511","FLT.AU","MQG.AU","IISV.AU","GEAR.AU","E200.AU","ISBC","OZF.AU","BK7046","XAO.AU","GIVE.AU","BK7508","QFN.AU","BK7043","VAS.AU","VAP.AU","STW.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649987762","title":"3 Australian Founder Led Stocks With Long Term Skin In The Game","url":"https://stock-news.laohu8.com/highlight/detail?id=2649987762","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649987762?lang=en_us&edition=fundamental","pubTime":"2026-07-07 17:29","pubTimestamp":1783416553,"startTime":"0","endTime":"0","summary":"With inflation risks tied to oil supply tensions, shifting rate expectations in the UK and mixed signals from central banks worldwide, many investors are looking for company level resilience rather than macro calls. Founder led businesses can offer that, as leaders with large personal stakes often think in terms of decades, not quarters. This Founder Led Companies screener focuses on those entrepreneurs and original builders who are still at the helm and deeply invested in outcomes. In this...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/4484222-main-header/1585186590706","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/4484222-main-header/1585186590706"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/consumer-services/asx-flt/flight-centre-travel-group-shares/news/3-australian-founder-led-stocks-with-long-term-skin-in-the-g","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/consumer-services/asx-flt/flight-centre-travel-group-shares/news/3-australian-founder-led-stocks-with-long-term-skin-in-the-g","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["XAO.AU","BK7067","VAS.AU","QFN.AU","VAP.AU","BK7046","AIPO","E200.AU","OZR.AU","BK7043","BK7070","MQG.AU","BK7508","FLT.AU","BK7511","QRE.AU","BK7042","IISV.AU","OZF.AU","BEAR.AU","BK7501","MAQ.AU","IIGF.AU","DACE.AU","EIGA.AU","XKO.AU","GIVE.AU","IMLC.AU","SLF.AU","XJO.AU","BBOZ.AU","STW.AU","GEAR.AU","ZYAU.AU","MSB.AU","IOZ.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649864106","title":"Mesoblast Requests Modular Review of BLA for Rexlemestrocel-l in End-stage Heart Failure with LVAD","url":"https://stock-news.laohu8.com/highlight/detail?id=2649864106","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649864106?lang=en_us&edition=fundamental","pubTime":"2026-07-06 15:45","pubTimestamp":1783323913,"startTime":"0","endTime":"0","summary":"July 1 (Reuters) - Mesoblast Ltd::*REQUESTS MODULAR REVIEW OF BLA FOR REXLEMESTROCEL-L IN END-STAGE HEART FAILURE WITH LVAD*REXLEMESTROCEL-L RECEIVES ORPHAN DRUG AND RMAT DESIGNATIONS*Further company ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nRSD6tn3Cb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","MSB.AU","BK7501","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649146316","title":"3 Founder Led ASX Stocks Retail Investors Are Watching For Management Alignment","url":"https://stock-news.laohu8.com/highlight/detail?id=2649146316","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649146316?lang=en_us&edition=fundamental","pubTime":"2026-07-06 06:25","pubTimestamp":1783290328,"startTime":"0","endTime":"0","summary":"With central banks turning slightly less aggressive, inflation pressures mixed across regions and services sectors holding up better than expected in many countries, investors are again paying closer attention to stock selection rather than just macro headlines. Founder-led companies can be especially interesting in this context, as leaders with significant personal stakes often focus on building long term legacies instead of chasing short term targets. This Founder-Led Companies screener is...","market":"sg","thumbnail":"https://images.simplywall.st/asset/company-cover/4484222-main-header/1585186590706","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/4484222-main-header/1585186590706"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/consumer-services/asx-flt/flight-centre-travel-group-shares/news/3-founder-led-asx-stocks-retail-investors-are-watching-for-m","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/consumer-services/asx-flt/flight-centre-travel-group-shares/news/3-founder-led-asx-stocks-retail-investors-are-watching-for-m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7511","FLT.AU","BK7046","MAQ.AU","MSB.AU","MQG.AU","BK7067","AIPO","BK7043","BK7501","ISBC","BK7070","BK4211","BK7508","BK7042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648015660","title":"Why Mesoblast (ASX:MSB) Is Up 9.3% After FDA Accepts Modular BLA Review For Rexlemestrocel-L","url":"https://stock-news.laohu8.com/highlight/detail?id=2648015660","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648015660?lang=en_us&edition=fundamental","pubTime":"2026-07-04 00:35","pubTimestamp":1783096506,"startTime":"0","endTime":"0","summary":"In late June 2026, Mesoblast received a Biologics License Application filing number from the U.S. FDA and requested modular review for rexlemestrocel-L to prevent life-threatening gastrointestinal bleeding in end-stage heart failure patients supported by left ventricular assist devices, building on its Orphan Drug and RMAT designations.\nThe filing comes as new FDA draft guidance reiterates a flexible approach to therapies for rare, high-mortality conditions, potentially aligning closely with...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/why-mesoblast-asxmsb-is-up-93-after-fda-accepts-modular-bla","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/why-mesoblast-asxmsb-is-up-93-after-fda-accepts-modular-bla","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4006","BK7508","BK4585","BK4588","LABU","MSB","BK7067","BK7501","MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648502120","title":"Founder Led Stocks Retail Investors Are Watching In Australia Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2648502120","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648502120?lang=en_us&edition=fundamental","pubTime":"2026-07-02 19:47","pubTimestamp":1782992868,"startTime":"0","endTime":"0","summary":"With inflation trends shifting, central banks reassessing rate paths and growth signals looking mixed, many investors are looking for leaders who are personally tied to the long term success of their companies. Founder led stocks can offer that kind of alignment because the people calling the shots often have much of their own wealth on the line too. This article uses a Founder Led Companies screener that focuses on that commitment. It then highlights 3 stocks from the list that stand out and...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/4484222-main-header/1585186590706","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/4484222-main-header/1585186590706"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/consumer-services/asx-flt/flight-centre-travel-group-shares/news/founder-led-stocks-retail-investors-are-watching-in-australi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/consumer-services/asx-flt/flight-centre-travel-group-shares/news/founder-led-stocks-retail-investors-are-watching-in-australi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MSB.AU","QFN.AU","FLT.AU","MQG.AU","IMLC.AU","OZR.AU","IIGF.AU","STW.AU","BBOZ.AU","BK7508","XKO.AU","BK7070","ISBC","IOZ.AU","IISV.AU","SLF.AU","ZYAU.AU","XAO.AU","OZF.AU","BEAR.AU","BK7042","DACE.AU","BK7511","GEAR.AU","BK7043","GIVE.AU","BK7501","MAQ.AU","QRE.AU","BK7046","XJO.AU","BK4211","BK7067","VAP.AU","EIGA.AU","VAS.AU","E200.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648957086","title":"Is Mesoblast (ASX:MSB) Undervalued Following FDA Progress For Rexlemestrocel L?","url":"https://stock-news.laohu8.com/highlight/detail?id=2648957086","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648957086?lang=en_us&edition=fundamental","pubTime":"2026-07-02 13:40","pubTimestamp":1782970812,"startTime":"0","endTime":"0","summary":"Why this FDA milestone matters for Mesoblast\nMesoblast (ASX:MSB) stock is in focus after the US FDA assigned a Biologics License Application filing number for rexlemestrocel-L and accepted a modular review request for patients with LVAD-related risks.\nThis regulatory step, supported by existing Orphan Drug and Regenerative Medicine Advanced Therapy designations, provides formal structure around the approval process for Mesoblast’s late-stage heart failure program and clarifies the path for...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/is-mesoblast-asxmsb-undervalued-following-fda-progress-for-r","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/is-mesoblast-asxmsb-undervalued-following-fda-progress-for-r","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4097","MSB","BK4006","MSB.AU","LABU","BK4585","PRGS","BK7067","LU2065732104.USD","BK7501","BK7508","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174776615","title":"Stock Track | Mesoblast Soars 5.12% Intraday on FDA BLA Filing Number for Rexlemestrocel-L Heart Failure Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=1174776615","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174776615?lang=en_us&edition=fundamental","pubTime":"2026-07-01 11:48","pubTimestamp":1782877717,"startTime":"0","endTime":"0","summary":"MESOBLAST LTD (MSB.AU) shares soared 5.12% during intraday trading on Wednesday, driven by a significant regulatory milestone for its lead therapy candidate.The biotech company announced it received...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648259980","title":"Mesoblast Receives Biologics License Application Filing Number From US FDA; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648259980","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648259980?lang=en_us&edition=fundamental","pubTime":"2026-07-01 10:01","pubTimestamp":1782871305,"startTime":"0","endTime":"0","summary":"Mesoblast  received a biologics license application  filing number from the US Food and Drug Administration  for rexlemestrocel-L in the prevention of gastrointestinal bleeding due to right ventricular dysfunction in end-stage heart failure patients with a left ventricular assist device, according to a Wednesday filing with the Australian bourse.BLA filing number is a six-digit tracking number issued by the FDA to identify and monitor a formal request to market a biologic product.The company also requested a modular review of its BLA for the therapy, the filing said.Shares rose 3% in morning trade on Wednesday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BLA.AU","MESO","BK7067","BK4585","MSB.AU","BK7501","BK4139","BK7508","LABU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":6,"totalSize":164,"code":"91000000","status":"200"}]}}